Company: SION
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0002036042-25-000005
Chunk: 208

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 208
---
 of December 31, 2024 and 2023; liquidation value of $25,263 as of December 31, 2024 and 202325,235 25,235 Series B convertible preferred stock, $0.001 par value, 11,370,621 shares authorized, issued and outstanding as of December 31, 2024 and 2023; liquidation value of $111,000 as of December 31, 2024 and 2023110,791 110,791 Series C convertible preferred stock, $0.001 par value, 18,628,970 and 0 shares authorized, issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation value of $181,856 as of December 31, 2024181,328 — Total convertible preferred stock330,368 149,040 Stockholders’ deficit:Common stock, $0.001 par value, 55,200,000 and 30,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 4,798,721 and 3,313,012 shares issued, 4,722,763 and 3,050,863 shares outstanding as of December 31, 2024 and 2023, respectively5 2 Additional paid-in capital17,000 4,515 Accumulated other comprehensive income368 — Accumulated deficit(181,086)(119,398)Total stockholders’ deficit(163,713)(114,881)Total liabilities, convertible preferred stock and stockholders’ deficit$185,752 $51,945 

The accompanying notes are an integral part of these consolidated financial statements. 

F-3

SIONNA THERAPEUTICS, INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(in thousands, except share and per share data) 

Year Ended December 31,20242023Operating expenses:Research and development$57,288 $40,626 General and administrative13,268 9,707 Total operating expenses70,556 50,333 Loss from operations(70,556)(50,333)Other income:Interest income8,170 2,769 Other income698 301 Total other income8,868 3,070 Net loss$(61,688)$(47,263)